An Elusive Fox that Suppresses Scgb1a1 in Asthma Has Been Found

Asthma is a worldwide chronic airways disease that affects more than 300 million children and adults worldwide (1). Affected individuals suffer from wheezing, chest tightness, shortness of breath, and cough that is attributed to airway narrowing, excessive mucus production, and persistent inflammation. Symptoms often begin in early childhood and are believed to be initiated by a severe inflammatory response in a developmentally immature immune system. Initiating factors include infection with rhinovirus or other respiratory viral infections, exposure to particulate matter such as tobacco smoke or air pollution, and even supplemental oxygen used to treat preterm infants. Asthma exacerbations typically occur after exercise, T-helper cell type 2 (Th2)-mediated allergic responses, respiratory infections, and exposure to various pulmonary irritants. Although it is a minor inconvenience for most individuals, asthma can be a major, life-threatening health concern for others. The key to understanding this variability lies in defining the complex gene–environment interactions that drive asthma and other airway diseases such as chronic obstructive pulmonary disease (COPD). In this issue of the Journal, Zhu and colleagues (pp. 695–704), report on what may be a key observation in furthering our understanding of why the airway epithelium of individuals with asthma or COPD have less secretoglobin family 1A member 1 (SCGB1A1; also known as club cell secretory protein [CCSP]), CC10, and CC16) compared with healthy control subjects (2). In their studies, they discovered that viral infections and Th2 cytokines inhibit expression of SCGB1A1 by inhibiting expression of the transcription factor forkhead box A2 (FOXA2), which is known to regulate Th2-mediated inflammation and goblet cell hyperplasia.

So why is this important? SCGB1A1 is a small homodimeric molecule that is secreted by nonciliated airway club cells and mucus-producing cells of the uterus. It is the most abundant protein found in airway lining fluid, and can be detected in serum and urine. Although its exact physiologic function has yet to be defined, SCGB1A1 possesses antiinflammatory and antioxidant properties via its ability to inhibit phospholipase A2 activity, sequester hydrophobic ligands such as polychlorinated biphenyls and steroids, alter chemotaxis, and affect cytokine production (3). These properties indicate that SCGB1A1 is an important defense molecule of the lung. Hence, it is not surprising that lower levels of SCGB1A1 have been detected in BAL fluid, serum, and urine of individuals with asthma or COPD compared with healthy control subjects (4). Similarly, airspace enlargement is greater in Scgb1a1-null mice exposed to cigarette smoke than wild-type controls. Additionally, several inflammatory and autoimmune diseases have been associated with a SNP in the Scgb1a1 gene, resulting in reduced levels of SCGB1A1 protein (5). Improving the respiratory health of individuals with asthma or COPD therefore requires a better understanding of how SCGB1A1 is suppressed.

To identify factors capable of suppressing SCGB1A1 in airways disease, Zhu and colleagues analyzed three previously published transcriptomic datasets of human brushed bronchial epithelial cells isolated from subjects with asthma and control subjects without asthma. They confirmed that individuals with asthma express less Scgb1a1 mRNA than those without asthma, and found that this correlated with reduced mRNA encoding FOXA2, a known transcriptional inducer of Scgb1a1 mRNA. The authors went on to show that 1) Scgb1a1 and FoxA2 were both suppressed in an ovalbumin mouse model of airway hyperreactivity, 2) the Th2 cytokines IL-4 and IL-13 suppressed epithelial expression of both FOXA2 and SCGB1A1, 3) rhinovirus infection inhibited epithelial expression of these two proteins, and 4) overexpression of FOXA2 stimulated Scgb1a1 transcription and abundance of SCGB1A1 protein. Perhaps most compelling is the observation that overexpression of FOXA2 restored expression of SCGB1A1 in epithelial cells treated with IL-13 or infected with rhinovirus. Collectively, these findings provide strong experimental evidence that two known mediators of airways disease, namely, rhinovirus and Th2 cytokines, can suppress epithelial expression of SCGB1A1 via inhibition of FOXA2 (Figure 1). Such knowledge may prove to be a critical key needed to restore expression of SCGB1A1 in the airways of individuals with asthma or COPD.

This discovery also raises new questions and opportunities for further research. The current study used Scgb1a1-null mice to show how complete loss of SCGB1A1 potentiates airway hyperreactivity and responsiveness to ovalbumin challenge. It remains to be determined how loss of SCGB1A1 affects airway function. A recent paper showing that Scgb1a1-null mice have higher levels of collagen and ACTA2 in their lungs than wild-type mice suggests that SCGB1A1 influences airway structure (6). An emerging concept is that individuals with asthma may have leaky airways that permit the transepithelial passage of inhaled allergens and other proinflammatory pollutants into the underlying interstitial space (7). Loss of SCGB1A1 may therefore reflect a change in the airway club cell phenotype and consequently a change in airway barrier integrity. Another study found a slow but steady loss of Scgb1a1 in irradiated mice infected with influenza A virus (8). Loss of SCGB1A1 was attributed to loss of club cells, perhaps because distal airway progenitor cells are radiosensitive (9). The slow loss of SCGB1A1 after radiation may be useful for defining a threshold of SCGB1A1 that correlates with increased airway hyperreactivity. It is also important to note that protein abundance does not always equate with functional activity. For example, increased oxidation of SCGB1A1 has been observed in tracheal aspirates of preterm infants who went on to develop bronchopulmonary dysplasia (10). Whether oxidation of SCGB1A1 impairs function and contributes
to the enhanced incidence of airway wheezing reported in preterm-born infants remains to be determined. Regardless, these types of studies suggest that loss of SCGB1A1 expression or activity can cause airways disease through multiple mechanisms that remain to be fully understood.

The study by Zhu and colleagues also raises the question of persistence. Specifically, why are SCGB1A1 and FOXA2 persistently suppressed even when the initial inflammatory response or infection has subsided? It is known that genetic deletion of FoxA2 in the developing respiratory epithelium promotes an asthmatic phenotype reflected in cell proliferation, differentiation, and longevity. A closer look in the lung may reveal other elusive Foxes that adversely affect pulmonary function and respiratory health.

In summary, the paper by Zhu and colleagues is important because it provides compelling evidence that Th2 cytokines and viral infections may drive asthma via epithelial loss of FOXA2 and consequently loss of SCGB1A1. We should remember that FOXA2 is one of 44 members in the forkhead family of transcription factors (15) and that these proteins play important roles in regulating the expression of genes involved in cell proliferation, differentiation, and longevity. A closer look in the lung may reveal other elusive Foxes that adversely affect pulmonary function and respiratory health.

Author disclosures are available with the text of this article at www.atsjournals.org.

Acknowledgment: The authors apologize to their colleagues whose research was not mentioned due to space constraints. They thank members of the O’Reilly lab and its collaborators for their support.

Rachel Warren, M.S.
Michael A. O'Reilly, Ph.D.
School of Medicine and Dentistry
University of Rochester
Rochester, New York

References

1. Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers 2015;1:15025.
2. Zhu L, An L, Ran D, Lizarraga R, Bondy C, Zhou X, et al. The club cell marker SCGB1A1 downstream of FOXA2 is reduced in asthma. Am J Respir Cell Mol Biol 2019;60:695–704.
3. Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: a steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily. Endocr Rev 2007;28:707–725.
4. Laucho-Contreras ME, Polverino F, Tesfaigzi Y, Pilon A, Celli BR, Owen CA. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD). Expert Opin Ther Targets 2016;20:869–883.
5. Laing IA, Hermans C, Bernard A, Burton PR, Goldblatt J, Le Souef PN. Association between plasma CC16 levels, the A38G polymorphism, and asthma. Am J Respir Crit Care Med 2000;161:124–127.
6. Zhai J, Insel M, Addison KJ, Stern DA, Pederson W, Dy A, et al. Club cell secretory protein deficiency leads to altered lung function. Am J Respir Crit Care Med 2019;199:302–312.
7. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol 2014;134:509–520.
8. Manning CM, Johnston CJ, Henady E, Miller JN, Reed CK, Lawrence BP, et al. Exacerbation of lung radiation injury by viral infection: the role of Clara cells and Clara cell secretory protein. Radiat Res 2013;179:617–629.
9. McConnell AM, Konda B, Kirsch DG, Stripp BR. Distal airway epithelial progenitor cells are radiosensitive to High-LET radiation. Sci Rep 2016;6:33455.

10. Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:155–161.

11. Wan H, Kaestner KH, Ang SL, Ikegami M, Finkelman FD, Stahlman MT, et al. Foxa2 regulates alveolarization and goblet cell hyperplasia. Development 2004;131:953–964.

12. Chen G, Wan H, Luo F, Zhang L, Xu Y, Lewkowich I, et al. Foxa2 programs Th2 cell-mediated innate immunity in the developing lung. J Immunol 2010;184:6133–6141.

13. Tang X, Liu XJ, Tian C, Su Q, Lei Y, Wu Q, et al. Foxa2 regulates leukotrienes to inhibit Th2-mediated pulmonary inflammation. Am J Respir Cell Mol Biol 2013;49:960–970.

14. Basseres DS, D’Alò F, Yeap BY, Löwenberg EC, Gonzalez DA, Yasuda H, et al. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer 2012;77:31–37.

15. Golson ML, Kaestner KH. Fox transcription factors: from development to disease. Development 2016;143:4558–4570.